Treatment of Poriomania

It is an object of the present invention to provide a pharmaceutical composition, which permits the inhibition of non-intentional motions such as poriomania and hyperkinesia without any inhibition of intentional motions and in particular to provide a pharmaceutical composition capable of treating patients suffering from, for instance, poriomania and hyperkinesia. Moreover, it is also an object of the present invention to provide a method of using running neuron-inhibitory substances. A pharmaceutical composition for treating a patient suffering from symptoms accompanied by non-intentional motions such as poriomania and hyperkinesia, comprising a substance capable of pre-synaptically or post- synaptically inhibiting the running neurons. A method of using such substances permits the preparation of a pharmaceutical composition for treating a patient suffering from symptoms accompanied with unintentional motions such as poriomania and hyperkinesia. In particular, the pharmaceutical composition comprises a member selected from the group consisting of GABAB receptor agonists, GABAA receptor agonists, and GABAA receptor-enhancing substances, or any combination thereof. Moreover, the foregoing problems can likewise be solved by providing a method of using such running neuron-inhibitory substances, which permits the preparation of a pharmaceutical composition for treating a patient suffering from the foregoing symptoms.